



## **National Cancer Conference BJCEN-MORÉ 2024**

### **Management of Cholangiocarcinoma**

\*\*\*\*\*

### **AI Revolution in Cancer Care**

**17 – 20 October 2024**

## **SCIENTIFIC AGENDA**

### **17 October 2024, Thursday**

**09:00 – 18:00** Registration

**14:00 – 14:20** Official Opening

Presentation of the BJCEN-MORÉ Annual Award – for contribution to Bulgarian clinical oncology

**14:20 – 15:40** Industry Satellite Symposium *Novartis*

Moderator: Assoc. Prof. J. Arabadjiev, MD, PhD

14:20 – 14:40 New moments in prostate and breast cancer treatment from the latest international scientific events

Assoc. Prof. J. Arabadjiev, MD, PhD

14:40 – 15:00 Successes in prostate cancer treatment – can we do more  
R. Mangaldjiev, MD

15:00 – 15:20 Possibilities of modern radioligand therapy

Assoc. Prof. V. Hadjiiska, MD, PhD

15:20 – 15:40 Adjuvant breast cancer treatment – what we have achieved and how it will be in the future

Assoc. Prof. A. Konsoulova, MD, PhD

**15:45 – 16:45** Industry Satellite Symposium *Swixx BioPharma*

**Cholangiocarcinoma – refining and personalizing therapy**

Moderator: M. Koleva, MD

15:45 – 16:05 Cholangiocarcinoma – current paradigms and principles  
R. Mangaldjiev, MD

16:05 – 16:25 The role of FGFR

Prof. S. Popovska, MD, PhD

16:25 – 16:45 Study FIGHT-202

Tc. Yordanov, MD



**16:45 – 17:00 Coffee Break**

**17:00 – 18:00 Industry Satellite Symposium Janssen (J&J)**  
**Current Therapeutic Opportunities by J&J Innovative Medicine**

Moderator: *Assoc. Prof. D. Kalev, MD, PhD*

17:00 – 17:05 Opening remarks

17:05 – 17:25 *Erleada*® and triplet therapy in the treatment of metastatic hormone-sensitive prostate cancer: How to evaluate treatment options

*R. Mangaljiev, MD*

17:25 – 17:45 *Rybrevant*®: The first immunotherapy approved for the treatment of patients with non-small cell lung cancer harboring EGFR Exon 20 insertion mutations

*K. Koynov, MD*

17:45 – 18:00 Discussion and closing remarks

Moderator: *Assoc. Prof. D. Kalev, MD, PhD*

**18:05 – 19:45 Industry Satellite Symposium Varia**

Moderator: *Assoc. Prof. J. Arabadjiev, MD, PhD*

18:05 – 18:25 Corporate presentation *Eli Lilly*

Treatment of patients with ER+, HER2– early breast cancer – High-risk therapy

*Assoc. Prof. A. Konsoulova, MD, PhD*

18:25 – 18:45 Corporate presentation *Astellas*

*Padcev*™ (*enfortumab vedotin*) – A journey beyond the horizon in the treatment of advanced urothelial carcinoma

*V. Kanarev, MD*

18:45 – 19:05 1<sup>st</sup> Corporate presentation *Roche*

Subcutaneous administration of *Tecentriq* as an opportunity to optimize the route of administration of immunotherapy

*Assoc. Prof. A. Konsoulova, MD, PhD*

19:05 – 19:25 2<sup>nd</sup> Corporate presentation *Roche*

Adjuvant *Alecensa*: a new therapeutic strategy in early ALK+ non-small cell lung carcinoma

*Assoc. Prof. J. Arabadjiev, MD, PhD*

19:25 – 19:45 Corporate presentation *Amgen*

Multi omics biomarker analyzes in metastatic colorectal carcinoma – practical significance for determining therapeutic behavior

*L. Simeonova, MD*

**20:00 Welcome Dinner**

**18 October 2024, Friday**

**07:00 – 19:00 Registration**

**08:00 – 10:40 1<sup>st</sup> PLENARY SESSION**

**Diagnostic and Pre-therapeutic Issues in Cholangiocarcinoma**

Chairmen: *Prof. S. Popovska, MD, PhD*



08:00 – 08:15 Elevation of serum biomarker CA19-9 in cholangiocarcinoma – benefits and dilemmas

*V. Koleva, MD*

08:20 – 08:35 Genomic landscape of cholangiocarcinoma types

*L. Balabanski, Prof. D. Toncheva, MD, PhD*

08:40 – 08:55 Molecular pathologic and clinical parallels between small and large duct intrahepatic cholangiocarcinoma

*Assoc. Prof. I. Ivanov, MD, Prof. S. Popovska, MD, PhD*

09:00 – 09:15 Histology of cholangiocarcinoma – beyond the ordinary

*Assoc. Prof. V. Ivanova, MD, PhD*

09:20 – 09:35 Classificatory and prognostic role of imaging features in intrahepatic cholangiocarcinoma

*Assoc. Prof. M. Penkov, MD, PhD, D. Videva, MD*

09:40 – 09:55 Imaging modalities for the assessment of resectability in perihilar cholangiocarcinoma

*Assoc. Prof. P. Getzov, MD, PhD*

10:00 – 10:15 PET/CT assessment of global burden of disease in cholangiocarcinoma – prognosis and prediction

*Prof. E. Piperkova, MD, PhD, Assoc. Prof. L. Chavdarova, MD, PhD, Prof. I. Kostadinova, MD, PhD*

10:20 – 10:35 PET/CT-based radiomics in cholangiocarcinoma – expected clinical benefits

*Assoc. Prof. V. Hadjiiska, MD, PhD*

**10:40 – 11:00 Coffee Break**

**11:00 – 13:00 2<sup>nd</sup> PLENARY SESSION**

**Invasive and Surgical Strategies for Cholangiocarcinoma (1)**

Chairmen: *Prof. N. Vladov, MD, PhD*

11:00 – 11:15 Pre-operative classifications of perihilar cholangiocarcinoma

*Assoc. Prof. V. Mihaylov, MD, PhD, C. Trichkov, MD*

11:20 – 11:35 Anomalous pancreaticobiliary confluence – a risk factor and indication for cholangiocarcinoma risk-reduction surgery

*Prof. A. Julianov, MD, PhD, A. Saroglu, MD*

11:40 – 11:55 Strategies for the liver remnant future optimization

*Assoc. Prof. C. Lukanova, MD, PhD, R. Kostadinov, MD*

12:00 – 12:15 Biliary drainage – in preoperative and/or advanced planning

*Assoc. Prof. A. Katzarov, MD, PhD*

12:20 – 12:35 Peritoneal cytology in cholangiocarcinoma – prognostic value

*Assoc. Prof. S. Bachurska, MD, PhD*

12:40 – 12:55 Vascular resections in cholangiocarcinoma

*Prof. D. Kostov, MD, PhD*

**13:00 – 14:00 Lunch**

**14:00 – 15:20 3<sup>rd</sup> PLENARY SESSION****Invasive and Surgical Strategies for Cholangiocarcinoma (2)**Chairmen: *Prof. N. Vladov, MD, PhD*

14:00 – 14:15 Peculiarities of surgical treatment in gallbladder cancer

*Assoc. Prof. N. Belev, MD, PhD*

14:20 – 14:35 When is reexploration necessary after routine cholecystectomy with incidentally discovered gallbladder cancer

*Prof. K. Draganov, MD, PhD, A. Petreska, MD*

14:40 – 14:55 Local strategies for perihilar and distal cholangiocarcinoma – evidence and recommendations

*Assoc. Prof. P. Karagyozov, MD, PhD*

15:00 – 15:15 Liver transplantation – how to select cholangiocarcinoma patients

*Prof. I. Takorov, MD, PhD***15:20 – 15:40 Coffee Break****15:40 – 18:20 4<sup>th</sup> PLENARY SESSION****Systemic and radiotherapy approaches in cholangiocarcinoma**Chairmen: *Assoc. Prof. A. Konsoulova, MD, PhD*

15:40 – 15:55 Arguments and reservations for neoadjuvant systemic therapy in resectable cholangiocarcinoma

*M. Taushanova, MD, K. Koynov, MD*

16:00 – 16:15 Definitive radiotherapy strategies for unresectable cholangiocarcinoma – Why, When, How

*Prof. T. Hadzhieva, MD, PhD, M. Koleva, MD*16:20 – 16:35 Adjuvant systemic therapy for resected cholangiocarcinoma – is *capecitabine* the standard*T. Zlatanova, MD*

16:40 – 16:55 Postoperative radiotherapy for gallbladder cancer and distal cholangiocarcinoma

*K. Jordanov, MD, K. Nedev, MD*

17:00 – 17:15 First- and second-line chemotherapy in cholangiocarcinoma – is the tradition relevant?

*Assoc. Prof. A. Konsoulova, MD, PhD*

17:20 – 17:35 Immunotherapy in advanced cholangiocarcinoma – present or future

*R. Mangaldjiev, MD*

17:40 – 17:55 Dietary issues during and after cholangiocarcinoma treatment

*Assoc. Prof. N. Jordanov, MD, PhD*

18:00 – 18:15 The role of cannabidiol in cholangiocarcinoma – from empiricism to evidence

*M. Koleva, MD*

**18:20 – 19:20 Industry Satellite Symposium Pfizer****More hope for patients with ALK+ non-small cell lung cancer and HR+/HER2– metastatic breast cancer**

Moderator: *Assoc. Prof. A. Konsoulova, MD, PhD*

18:20 – 18:40 Exceptional over 5-year PFS in first-line treatment of ALK+ NSCLC  
*K. Koynov, MD*

18:40 – 19:00 A personalized approach in patients with HR+/HER2– metastatic breast cancer based on real-world data  
*P. Balikova, MD*

19:00 – 19:20 Discussion

Moderator: *Assoc. Prof. A. Konsoulova, MD, PhD*

**19:25 – 20:15 1<sup>st</sup> JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK****Integrative Oncology and Dietetics**

Chairmen: *P. Zagorchev, MD*

19:25 – 19:45 Homeopathic supportive care in oncology: Focus on surgical monitoring and diarrhea

*J-C. Karp, MD* (Troyes University Hospital, France)

19:50 – 20:15 Nutrition specificity in cholangiocarcinoma

*Prof. D. Naydenova, MD, PhD*

**20:30 Dinner**

**19 October 2024, Saturday**

**07:00 – 18:00 Registration**

**08:00 – 09:15 2<sup>nd</sup> JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK****Deep-Health Tech and Artificial Intelligence (AI) in Cancer Care – Convergence**

Moderators: *M. Ganova* (DHI Bulgaria), *I. Lekushev* (BGO Software)

Panel discussion with: *H. Ivanov* (Shemha Health), *P. Mihailov* (MY Synergy), *G. Kostadinov* (Kelvin Health), *V. Tafrajiisky* (Software Company)

**09:20 – 10:20 Industry Satellite Symposium MSD**

Moderator: *Assoc. Prof. D. Kalev, MD, PhD*

09:20 – 09:25 Opening remarks

09:25 – 09:45 *Pembrolizumab* treatment options for esophageal carcinoma  
*Iv. Nikolov, MD*

09:45 – 10:05 The place of *Pembrolizumab* in the management of HER2-positive gastric or gastroesophageal junction carcinoma  
*K. Koynov, MD*

10:05 – 10:20 Discussion and closing remarks

Moderator: *Assoc. Prof. D. Kalev, MD, PhD*

**10:20 – 10:40 Coffee Break**

**10:40 – 11:40 Industry Satellite Symposium Pierre Fabre**

Moderators: *G. Shalamanova, MD, and Assoc. Prof. I. Gavrilova, MD*

The role of targeted therapy in melanoma treatment in 2024

*Prof. H. Gogas, MD*

**11:45 – 13:00 3<sup>rd</sup> JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK  
Artificial Intelligence (AI) in Cancer Care – Ethic, Clinical and Regulatory Norms  
in Bulgaria**

Moderator: *Assoc. Prof. B. Borissov, MD, PhD*

Panel discussion with: *Prof. M. Lazarova* (Legal Expert), *Petya Murgova* (Law office Murgova and partners), *D. Denev* (ARPharM), *A. Simidchiev, MD* (Chairman of the Parliamentary Healthcare Commission, Member of the Bulgarian Parliament), *R. Mangaldjiev, MD* (Medical Oncologist), *Assoc. Prof. J. Arabadjiev, MD, PhD* (Board member EU Mission on Cancer; President of Bulgarian Scientific Society of Immunology), *S. Hasardjiev, MD* (President of National Patient Organization, Bulgaria)

**13:00 – 14:00 Lunch****14:00 – 15:15 4<sup>th</sup> JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK  
Artificial Intelligence (AI) in Cancer Care: Sustainable Systems Solutions –  
Innovative Approaches for Efficiency**

Moderator: *G. Kapetanakis* (President of the Hellenic Cancer Federation – ELLOK)

Panel discussion with: *E. Pisani* (CEO, All.Can International), *D. Georgiev, MD* (Bulgarian Association for Personalized Medicine), *Prof. B. Vassileva* (Vice-Rector of University of Economics – Varna), *I. Cattaneo* (EFPIA Oncology Working Group), *M. Stoycheva* (ex-Minister of Ministry of Innovations and Growth, Bulgaria), *A. Simidchiev, MD* (Chairman of the Parliamentary Healthcare Commission, Member of the Bulgarian Parliament)

**15:20 – 16:35 5<sup>th</sup> JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK  
Artificial Intelligence (AI) in Cancer Care: Sustainable Systems Solutions –  
Policies, Sustainable and Impactful Practices**

Moderator: *M. Geanta, MD* (President of the Center for Innovation in Medicine, Romania)

Panel discussion with: *R. Price* (European Cancer Organization), *P. Gunther* (Board EU Cancer Mission), *Ch. Chomienne* (Vice Chair of the EU Cancer Mission), *A. Kovatchev, PhD* (Member of European Parliament)

**16:40 – 17:00 Coffee Break****17:00 – 18:00 Industry Satellite Symposium AstraZeneca**

**A significant step forward in the treatment of genitourinary and gastrointestinal carcinoma**

**17:00 – 17:25 Genitourinary Carcinoma Module**

Establish an approach in the treatment of mCRPC

*K. Koynov, MD*



**17:25 – 18:00 Gastrointestinal Carcinoma Module**

Moderator: *Assoc. Prof. J. Arabadjiev, MD, PhD*

17:25 – 17:40 Long-term benefit in the treatment of unresectable or metastatic bile duct carcinoma

*Assoc. Prof. J. Arabadjiev, MD, PhD*

17:40 – 18:00 A significant step forward in the treatment of hepatocellular carcinoma with IO-IO

*M. Koleva, MD*

**18:05 – 18:35 Industry Satellite Symposium BMS**

**Immuno-oncology in gastroesophageal tumors: pathways to better treatment**

Moderator: *Assoc. Prof. Assya Konsoulova, MD*

18:05 – 18:15 Histological features of gastroesophageal tumors

*Assoc. Prof. S. Bachurska, MD, PhD*

18:15 – 18:25 CheckMate 649: Advanced carcinoma of the stomach, gastroesophageal junction, and esophagus

*V. Marinova, MD*

18:25 – 18:35 From trials to practice - sharing clinical experience

*Ir. Koleva, MD*

**18:40 – 20:00 6<sup>th</sup> JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK  
From Establishing of Cancer Mission Hubs: Networks and Synergies (ECHO<sub>S</sub>)  
toward the Bulgarian National Cancer Mission Hub (NCMH)**

Moderator: *Assoc. Prof. J. Arabadjiev, MD, PhD (Board member EU Mission on Cancer)*

Panel discussion with: *A. Isidro* (ECHO<sub>S</sub> Coordinator), *G. Kapetanakis* (President of the Hellenic Cancer Federation – ELLOK), *M. Geanta* (President of the Center for Innovation in Medicine, Romania), *Assoc. Prof. A. Konsoulova, MD, PhD* (Board Member of BJCN), *I. Petrov* (Public Affairs & Projects Lead at BJCN), *I. Cattaneo* (ECHO<sub>S</sub> Advisory Board Member), *Prof. S. Popovska* (Medical University – Pleven)

**20:30 Official Dinner**

**20 October 2024, Sunday**

**09:00 – 12:00 GENERAL ASSEMBLY OF BULGARIAN JOINT CANCER NETWORK (BJCN)**

**12:00 – 12:10 Official Closing**

